FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a market perform rating on shares of FibroGen in a research note on Monday, June 3rd.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $0.42 on Thursday. The stock has a 50 day moving average price of $0.60 and a 200 day moving average price of $1.11. The stock has a market capitalization of $41.38 million, a PE ratio of -0.17 and a beta of 0.69. FibroGen has a 52 week low of $0.33 and a 52 week high of $2.93.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to analyst estimates of $33.00 million. During the same period in the previous year, the company posted ($0.65) EPS. As a group, research analysts forecast that FibroGen will post -0.91 EPS for the current year.

Institutional Trading of FibroGen

A number of hedge funds have recently made changes to their positions in the business. Alpine Global Management LLC bought a new stake in FibroGen in the 1st quarter valued at $25,000. Delap Wealth Advisory LLC bought a new stake in shares of FibroGen during the 1st quarter worth about $27,000. Accel Wealth Management bought a new stake in shares of FibroGen during the 1st quarter worth about $103,000. Point72 DIFC Ltd grew its stake in FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the last quarter. Finally, Doheny Asset Management CA bought a new position in FibroGen in the 2nd quarter valued at about $48,000. 72.71% of the stock is owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.